Drug-induced hyperbilirubinemia and the clinical influencing factors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ah, Young-Mi | - |
dc.contributor.author | Kim, Young-Mi | - |
dc.contributor.author | Kim, Min-Jung | - |
dc.contributor.author | Choi,Young Hee | - |
dc.contributor.author | Park, Kyoung-Ho | - |
dc.contributor.author | Son, In-Ja | - |
dc.contributor.author | Kim, Sang Geon | - |
dc.date.accessioned | 2021-06-23T17:04:36Z | - |
dc.date.available | 2021-06-23T17:04:36Z | - |
dc.date.issued | 2008-10 | - |
dc.identifier.issn | 0360-2532 | - |
dc.identifier.issn | 1097-9883 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/42154 | - |
dc.description.abstract | Hyperbilirubinemia may accompany harmful effects such as jaundice, brain dysfunction, and pharmacokinetic alterations of drugs. Clinical drugs are the important causes of hyperbilirubinemia, especially for patients with certain pathologic conditions or with genetic variations. This article reviews hyperbilirubinemic pathophysiology with respect to the effects of clinical drugs. In addition, this review introduces a new formula that may be utilized to estimate the annual occurrences of drug-induced hyperbilirubinemia in a hospital. Variations in the genes of UDP-glucuronosyltransferases, organic anion-transporting polypeptides and multidrug resistance proteins are the predisposing factors for drug-induced hyperbilirubinemia; therefore, their genetic and ethnic polymorphisms are discussed. | - |
dc.format.extent | 27 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.title | Drug-induced hyperbilirubinemia and the clinical influencing factors | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1080/03602530802341133 | - |
dc.identifier.scopusid | 2-s2.0-54549113284 | - |
dc.identifier.wosid | 000260325500001 | - |
dc.identifier.bibliographicCitation | DRUG METABOLISM REVIEWS, v.40, no.4, pp 511 - 537 | - |
dc.citation.title | DRUG METABOLISM REVIEWS | - |
dc.citation.volume | 40 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 511 | - |
dc.citation.endPage | 537 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DUBIN-JOHNSON-SYNDROME | - |
dc.subject.keywordPlus | SINGLE NUCLEOTIDE POLYMORPHISMS | - |
dc.subject.keywordPlus | ANION TRANSPORTING POLYPEPTIDE | - |
dc.subject.keywordPlus | BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE | - |
dc.subject.keywordPlus | OF-THE-LITERATURE | - |
dc.subject.keywordPlus | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | - |
dc.subject.keywordPlus | RENAL-TRANSPLANT RECIPIENTS | - |
dc.subject.keywordPlus | RESISTANCE PROTEIN-2 GENE | - |
dc.subject.keywordPlus | HEALTHY JAPANESE SUBJECTS | - |
dc.subject.keywordPlus | CHOLESTATIC LIVER-INJURY | - |
dc.subject.keywordAuthor | Hyperbilirubinemia | - |
dc.subject.keywordAuthor | UGT1A1 | - |
dc.subject.keywordAuthor | OATP1B1 | - |
dc.subject.keywordAuthor | Multidrug resistance-associated protein 2 (MRA2) | - |
dc.subject.keywordAuthor | Genetic polymorphisms | - |
dc.subject.keywordAuthor | Annual occurrence indices | - |
dc.subject.keywordAuthor | Adverse drug reactions | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/03602530802341133 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.